The United States of America, As Represented by the Secretary, Department of Health and Human Services

Christopher E Ramsden

Gregory S Keyes

Ruin Moaddel

Luigi Ferrucci

Myriam Gorospe

Kotb Abdelmohsen

Martina Rossi

This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: R, R, and Rare independently hydrogen or lower alkyl, Ris lower alkyl, hydroxyl, carboxyl, or amine, Ris hydrogen, lower alkyl, or halide, Ris hydroxyl or substituted thiol, and each Ris independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.

Fatty acid derivatives and their use

Gingerenone A prodrug compounds have a structure according to Formula I, or a pharmaceutically acceptable salt thereof wherein one of Rand Ris H or —C(O)—R and the other of Rand Ris —C(O)—R. Each R independently is Ror, where Ris C-Calkenyl, and Ris an amino acid side chain. The compounds are useful for inhibiting or eliminating senescence. The compounds may be administered to a subject having a senescence-associated disease or disorder, neuroinflammation, pain, and/or an amino acid deficiency.

Gingerenone A prodrugs as sensotherapeutics and methods of use

Growing community of inventors

Bethesda, MD, United States of America

Christopher E Ramsden